Reappraisal of Published Randomized LUTS/BPH Clinical Trials–What Have We Learned and Where Do We Stand?

索引

00:00 1.
Reappraisal of Published Randomized LUTS/BPH Clinical Trials –What Have We Learned and Where Do We Stand?
02:37 2.
Dr. Charles Sydney Burwell, Dean, Harvard Medical School 1935-49
03:56 3.
請問蒲永孝教授講話比較有公信力還是王炯珵醫師?
04:29 4.
Slide 4
05:48 5.
Guidelines Include Algorithms to Illustrate Medical Treatment Choices According to Evidence-based Medicine and Patients’ Profiles
06:04 6.
Recommendations for Treatment of Men with BPH Have Evolved in Line With Available Clinical Evidence
06:49 7.
VACOOP study
07:54 8.
ALFIN Study
09:20 9.
What does the guidelines recommend?
10:01 10.
PREDICT study
10:56 11.
What does the guidelines recommend?
10:57 12.
PREDICT study
11:21 13.
MTOPS Study
13:30 14.
Guideline Update
14:04 15.
Learning From Clinical Trial Experience
14:26 16.
Prostate volume: Higher Baseline PV Associated With an Increase in BPH Progression Events in MTOPS
15:20 17.
PSA: Higher Baseline PSA Associated With an Increase in BPH Progression Events in MTOPS
16:01 18.
CombAT study is Designed to Investigate the Efficacy and Safety of Combination Therapy in Men with m-s Symptoms of BPH and at Risk of Clinical Progression
17:02 19.
CombAT Study
18:14 20.
Combination Therapy Significantly Reduces the Relative Risk of AUR and/or BPH-related Surgery at 4 years
18:49 21.
Combination Therapy Reduces Risk of AUR, BPH-related Surgery and BPH Clinical Progression
19:27 22.
Dutasteride Plus Tamsulosin Provided Significantly Greater Symptom Benefit Than Either Monotherapy
20:16 23.
Drug Adherence
21:23 24.
Choose the Right Population for Study
21:47 25.
Entry Criteria for CombAT Included a BPH Population at Higher Risk of Progression Than MTOPS
22:54 26.
Differences between MTOPS and CombAT in the population under study
23:55 27.
Long-term Benefit of 5-ARI and α1-Blocker Combination Therapy1,2,3
25:09 28.
Slide 26
26:11 29.
Create More Benefits by Designing Following Study to Fill the Data Gap
26:28 30.
Understanding the Study Patient Populations
26:59 31.
Rationale for the CONDUCT StudyAdds to existing evidence
27:43 32.
CONDUCT: Study Design
27:58 33.
CONDUCT 最偉大的地方: 30min衛教
29:29 34.
Slide 32
30:08 35.
Efficacy: Mean IPSS at Each Visit
30:28 36.
Study Results: IPSS Change
30:45 37.
Efficacy: BPH Clinical Progression1
30:59 38.
CONDUCT Results: Summary1,2
31:15 39.
Dig Out Useful Evidence Beyond Studies by Post-hoc Analysis
31:26 40.
5ARI Prostate Cancer Risk Reduction Studies
32:30 41.
Slide 39
32:50 42.
Slide 40
34:24 43.
Slide 41
35:07 44.
Take Home Messages
35:09 45.
Slide 41
35:40 46.
Take Home Messages

筆記 (0)

未登入或權限不足!

討論

00:00 1.
Reappraisal of Published Randomized LUTS/BPH Clinical Trials –What Have We Learned and Where Do We Stand?
02:37 2.
Dr. Charles Sydney Burwell, Dean, Harvard Medical School 1935-49
03:56 3.
請問蒲永孝教授講話比較有公信力還是王炯珵醫師?
04:29 4.
Slide 4
05:48 5.
Guidelines Include Algorithms to Illustrate Medical Treatment Choices According to Evidence-based Medicine and Patients’ Profiles
06:04 6.
Recommendations for Treatment of Men with BPH Have Evolved in Line With Available Clinical Evidence
06:49 7.
VACOOP study
07:54 8.
ALFIN Study
09:20 9.
What does the guidelines recommend?
10:01 10.
PREDICT study
10:56 11.
What does the guidelines recommend?
10:57 12.
PREDICT study
11:21 13.
MTOPS Study
13:30 14.
Guideline Update
14:04 15.
Learning From Clinical Trial Experience
14:26 16.
Prostate volume: Higher Baseline PV Associated With an Increase in BPH Progression Events in MTOPS
15:20 17.
PSA: Higher Baseline PSA Associated With an Increase in BPH Progression Events in MTOPS
16:01 18.
CombAT study is Designed to Investigate the Efficacy and Safety of Combination Therapy in Men with m-s Symptoms of BPH and at Risk of Clinical Progression
17:02 19.
CombAT Study
18:14 20.
Combination Therapy Significantly Reduces the Relative Risk of AUR and/or BPH-related Surgery at 4 years
18:49 21.
Combination Therapy Reduces Risk of AUR, BPH-related Surgery and BPH Clinical Progression
19:27 22.
Dutasteride Plus Tamsulosin Provided Significantly Greater Symptom Benefit Than Either Monotherapy
20:16 23.
Drug Adherence
21:23 24.
Choose the Right Population for Study
21:47 25.
Entry Criteria for CombAT Included a BPH Population at Higher Risk of Progression Than MTOPS
22:54 26.
Differences between MTOPS and CombAT in the population under study
23:55 27.
Long-term Benefit of 5-ARI and α1-Blocker Combination Therapy1,2,3
25:09 28.
Slide 26
26:11 29.
Create More Benefits by Designing Following Study to Fill the Data Gap
26:28 30.
Understanding the Study Patient Populations
26:59 31.
Rationale for the CONDUCT StudyAdds to existing evidence
27:43 32.
CONDUCT: Study Design
27:58 33.
CONDUCT 最偉大的地方: 30min衛教
29:29 34.
Slide 32
30:08 35.
Efficacy: Mean IPSS at Each Visit
30:28 36.
Study Results: IPSS Change
30:45 37.
Efficacy: BPH Clinical Progression1
30:59 38.
CONDUCT Results: Summary1,2
31:15 39.
Dig Out Useful Evidence Beyond Studies by Post-hoc Analysis
31:26 40.
5ARI Prostate Cancer Risk Reduction Studies
32:30 41.
Slide 39
32:50 42.
Slide 40
34:24 43.
Slide 41
35:07 44.
Take Home Messages
35:09 45.
Slide 41
35:40 46.
Take Home Messages

分享
- Facebook
- Twitter
- LinkedIn
- 嵌入網址
- QR code

索引
筆記
討論
全螢幕

Reappraisal of Published Randomized LUTS/BPH Clinical Trials–What Have We Learned and Where Do We Stand?

長度: 38:16, 瀏覽: 772, 最近修訂: 2017-05-19

00:00 1.
Reappraisal of Published Randomized LUTS/BPH Clinical Trials –What Have We Learned and Where Do We Stand?
02:37 2.
Dr. Charles Sydney Burwell, Dean, Harvard Medical School 1935-49
03:56 3.
請問蒲永孝教授講話比較有公信力還是王炯珵醫師?
04:29 4.
Slide 4
05:48 5.
Guidelines Include Algorithms to Illustrate Medical Treatment Choices According to Evidence-based Medicine and Patients’ Profiles
06:04 6.
Recommendations for Treatment of Men with BPH Have Evolved in Line With Available Clinical Evidence
06:49 7.
VACOOP study
07:54 8.
ALFIN Study
09:20 9.
What does the guidelines recommend?
10:01 10.
PREDICT study
10:56 11.
What does the guidelines recommend?
10:57 12.
PREDICT study
11:21 13.
MTOPS Study
13:30 14.
Guideline Update
14:04 15.
Learning From Clinical Trial Experience
14:26 16.
Prostate volume: Higher Baseline PV Associated With an Increase in BPH Progression Events in MTOPS
15:20 17.
PSA: Higher Baseline PSA Associated With an Increase in BPH Progression Events in MTOPS
16:01 18.
CombAT study is Designed to Investigate the Efficacy and Safety of Combination Therapy in Men with m-s Symptoms of BPH and at Risk of Clinical Progression
17:02 19.
CombAT Study
18:14 20.
Combination Therapy Significantly Reduces the Relative Risk of AUR and/or BPH-related Surgery at 4 years
18:49 21.
Combination Therapy Reduces Risk of AUR, BPH-related Surgery and BPH Clinical Progression
19:27 22.
Dutasteride Plus Tamsulosin Provided Significantly Greater Symptom Benefit Than Either Monotherapy
20:16 23.
Drug Adherence
21:23 24.
Choose the Right Population for Study
21:47 25.
Entry Criteria for CombAT Included a BPH Population at Higher Risk of Progression Than MTOPS
22:54 26.
Differences between MTOPS and CombAT in the population under study
23:55 27.
Long-term Benefit of 5-ARI and α1-Blocker Combination Therapy1,2,3
25:09 28.
Slide 26
26:11 29.
Create More Benefits by Designing Following Study to Fill the Data Gap
26:28 30.
Understanding the Study Patient Populations
26:59 31.
Rationale for the CONDUCT StudyAdds to existing evidence
27:43 32.
CONDUCT: Study Design
27:58 33.
CONDUCT 最偉大的地方: 30min衛教
29:29 34.
Slide 32
30:08 35.
Efficacy: Mean IPSS at Each Visit
30:28 36.
Study Results: IPSS Change
30:45 37.
Efficacy: BPH Clinical Progression1
30:59 38.
CONDUCT Results: Summary1,2
31:15 39.
Dig Out Useful Evidence Beyond Studies by Post-hoc Analysis
31:26 40.
5ARI Prostate Cancer Risk Reduction Studies
32:30 41.
Slide 39
32:50 42.
Slide 40
34:24 43.
Slide 41
35:07 44.
Take Home Messages
35:09 45.
Slide 41
35:40 46.
Take Home Messages

位置

資料夾名稱

2015臺大攝護祭-醫藥護人員場

發表人

系統管理者

單位

泌尿部

建立

2017-05-19 17:14:21

最近修訂

2017-05-19 19:40:04

長度

38:16